From tumor size andHER2status to systems oncology for very early breast cancer treatment

Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?

“…However, even in this case, the net response rate of this agent added to chemotherapy is 10%, although the overall benefit of chemotherapy plus trastuzumab is 40% [15]. Given the concerns that this generation of targeted agents either provides no therapeutic benefit or, in a few cases, may simply delay the occurrence of recurrence [16], longer followup results are anticipated to enable robust conclusions about whether trastuzumab or other HER2 signaling pathway inhibitors can have long-term effects, resulting in a true cure.…”

Laparoscopic total gastrectomy: further progress in gastric cancer

“…We have started to understand complex molecular mechanisms underlying cancer and the tremendous complexity of multiple interacting genes and proteins as well as the interactions between environmental exposures and small molecules [21]. An exiting research road has already been opened for more effective molecular targeting therapy and personalized cancer medicine [29][30][31][32][33][34][35][36][37]. However, laparoscopic or robotic gastrectomy for improving QOL is already here to stay as the treatment of choice in both the East and the West.…”

Monitoring and assessing the intraabdominal therapeutic response for gastric cancer: is second-look laparoscopy the solution?

“…Excellent basic and translational research in the fields of genetics, personal genomics, and systems approaches is underway for the development of novel biomarkers and new therapies. But despite the optimism arising from the application of next-generation DNA sequencing, the time required for integration of robust markers and targeted agents will be long [3,14,[26][27][28][29][30][31][32][33][34][35].…”